Sitagliptin has a strong clinical profile and the potential to revolutionise the treatment of type 2 diabetes for millions of people who do not achieve the targeted blood sugar level with currently available anti-diabetic medications.
Cadila Pharmaceuticals has launched the generic versions of Sitagliptin in India under the brand names Jankey & Sitenali to address type 2 diabetes. Sitagliptin is a drug from the class of DPP-4 inhibitors, and a one-ofits-kind drug for the treatment of high glucose levels in the blood, also known as hyperglycaemia. High blood glucose can lead to such as atherosclerosis, stroke, heart attack, retinopathy, neuropathy and nephropathy. According to a recently published report, approximately 7.7 core people in India are suffering from diabetes. Metformin is presently the drug of choice for controlling blood glucose levels, but in the majority of the patients, it either does not provide optimum control or is not tolerated. Cadila has made a foray into the diabetes care segment with the launch of Sitenali and Jankey, having cardio-safe gliptin sitagliptin. It has also launched a potent combination of Sitagliptin and Metformin and branded it as Jankey M.
